Sugi Predict

Sugi Predict / Compounds / SCHEMBL1670220

SCHEMBL1670220

SCHEMBL1670220

O=C1Nc2cc(Br)ccc2OC12CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ALPL P05186 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ ALPI P09923 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ ALPG P10696 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TLR9 Q9NR96 1/20 0.43
▸ AHR P35869 2/20 0.41
▸ CMA1 P23946 1/20 0.41
▸ PDE3B Q13370 1/20 0.37
▸ PDE3A Q14432 1/20 0.37
▸ HTT P42858 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ F2 P00734 1/20 0.36
▸ TGM2 P21980 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26311289 0.94 LMNA (0.44) LMNAMAPTL3MBTL1MEN1ALPL
SCHEMBL2241730 0.91 LMNA (0.42) LMNAMAPTL3MBTL1MEN1ALPL
SCHEMBL25026431 0.87 L3MBTL1 (0.41) LMNAMAPTL3MBTL1MEN1ALPL
SCHEMBL24427664 0.87 LMNA (0.43) LMNAMAPTL3MBTL1MEN1ALPL
SCHEMBL31693946 0.81 LMNA (0.44) LMNAMAPTL3MBTL1MEN1ALPL
SCHEMBL13090980 0.80 MMP12 (0.53) MAPTGAAPDE3BPDE3AHTT
SCHEMBL13007732 0.80 MAPT (0.40) LMNAMAPTL3MBTL1MEN1GAA
SCHEMBL23553026 0.80 L3MBTL1 (0.39) LMNAMAPTL3MBTL1MEN1ALPL
SCHEMBL30016086 0.78 LMNA (0.42) LMNAMAPTL3MBTL1MEN1ALPL
SCHEMBL28645090 0.78 LMNA (0.42) LMNAMAPTL3MBTL1MEN1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025092818-A1 PYRIDINE DERIVATIVE AND USE THEREOF IN MEDICINE 康百达（四川）生物医药科技有限公司 2025-05-08 — — WO disclosed
CN-119462695-A Pyridine derivative and application thereof 康百达（四川）生物医药科技有限公司 2025-02-18 — — CN disclosed
WO-2023178035-A1 MULTICYCLIC COMPOUNDS SLAP PHARMACEUTICALS LLC (US) 2023-09-21 — — WO disclosed
US-RE49080-E1 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2022-05-24 — — US disclosed
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity UCB BIOPHARMA SPRL (BE) 2019-05-14 — — US disclosed
EP-3080115-B1 FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-05-08 — — EP disclosed
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 — — US disclosed
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 — — US disclosed
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity UCB S.A. (BE) 2018-05-17 — — US disclosed
EP-3303318-A1 BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2018-04-11 — — EP disclosed
US-20120178680-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2012-07-12 — — US disclosed
US-20120178680-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2012-07-12 — — US disclosed
US-8163704-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2012-04-24 — — US disclosed
US-8163704-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2012-04-24 — — US disclosed
US-8163704-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2012-04-24 — — US disclosed
US-20110171159-A1 Glycoside Derivatives and Uses Thereof NOVARTIS AG (CH) 2011-07-14 — — US disclosed
US-20110171159-A1 Glycoside Derivatives and Uses Thereof NOVARTIS AG (CH) 2011-07-14 — — US disclosed
US-20110171159-A1 Glycoside Derivatives and Uses Thereof NOVARTIS AG (CH) 2011-07-14 — — US disclosed
WO-2011048112-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2011-04-28 — — WO disclosed
WO-2011048112-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2011-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178680-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 LMNA 3972/4885MAPT 1112/4885L3MBTL1 4466/4885
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity TNF, NFKBIA, TNFRSF1A LMNA 2073/4885MAPT 2775/4885L3MBTL1 3823/4885
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity TNF, TNFRSF1A, NFKBIA LMNA 1964/4885MAPT 4148/4885L3MBTL1 3149/4885
US-20110171159-A1 Glycoside Derivatives and Uses Thereof SLC5A1, SLC5A2, SLC2A1 LMNA 3972/4885MAPT 1112/4885L3MBTL1 4466/4885
US-10005774-B2 Syk inhibitors SYK, BTK, LYN LMNA 4499/4885MAPT 4131/4885L3MBTL1 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.